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ABSTRACT 
A PHARMACOKINETIC MODEL 
OF THE LIVER 
by 
Samirbhai Rameshbhai Patel 
The liver is the major organ where chemical breakdown of organic and inorganic 
compounds takes place. A pharmacokinetic heterogeneous model was developed for the 
local anesthetic and antiarrhythmic drug lidocaine. It was assumed that transport and 
elimination of lidocaine and its metabolites are linear with concentration. Simulations 
were done using VisSim software on a 486 based personal computer to obtain 
concentration profiles for hepatic clearance and for step input of the drug and its 
metabolites. It was found that the rate of uptake and rate of breakdown were 0.48 
min 	 and 0.49 m 	 respectively for lidocaine. The results are consistent with 
published data. Similar simulations were done for the lidocaine metabolites MEGX and 
3-OHLID. 
The same heterogeneous model was used with appropriate changes to include 
cellular inactivation of the drug and urine output in order to model another 
antiarrthymic drug, procainamide. Simulations were done for hepatic clearance and for 
bolus (impulse) input to the model. The rate of uptake and rate of release for 
procainamide were found to be 9.35 min-1. The rate of breakdown and urine output 
were 0.0053 min-1  and 0.0013 min-1 respectively. 
Finally, a parameter sensitivity study was done for both lidocaine and its 
metabolites and procainamide in order to determine sensitivity of the model to the 
parameters used. The maximum values of rate constants for which the model can 
operate in stable range were determined. 
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CHAPTER 1 
INTRODUCTION 
The liver is the primary organ for metabolism of a wide range of lipophilic compounds, 
including many drugs, aromatic hydrocarbons, and chlorinated compounds [1]. Within 
the liver, a number of different physiological processes combine to give observed 
differences in drug elimination. Net changes in concentration of these compounds are due 
to a series of steps [2] summarized as follows; 
(1) The net flow of blood (perfusion medium) in the vascular network of the organ. 
(2) Uptake of the substrate from the vasculature into the liver cells. 
(3) Enzyme mediated reactions within the cells. 
(4) Release of metabolic products and unconverted substrate from the cells into the 
sinusoids. 
It is necessary to understand each of these processes to fully comprehend the 
overall process of drug elimination. Thus, a drug elimination model was developed by 
considering the above processes either individually or by grouping some of them with 
appropriate approximations. The major purpose of this model is to mathematically 
describe the dominant physiological processes that are occurring. The distribution of 
most drugs from the blood into highly perfused tissues such as liver and kidney is known 
to be quite rapid and that distribution in to moderately to poorly perfused tissues such as 
muscles and fat is rather slow [3]. This study is part of the whole body pharmacokinetic 
model for blood flow. Anesthetic and antiarrthymic drug model of liver was developed. 
1.1 Liver Physiology and Functions 
The liver is located in the blood stream between the gastrointestinal tract and spleen and 
vena cava leading to the heart. The liver can be regarded as a three dimensional, slowly 
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moving lake of blood in which sheets of liver cells, or hepatocytes float [4]. Blood 
enters the organ through both the portal vein and the hepatic artery and leaves the liver 
via the hepatic vein (Figure 1.1). The portal vein, hepatic vein, and hepatic artery are all 
subject to branching. Individual branches serve each lobe of the liver [5]. The blood flow 
to the liver is normally about 25% of the cardiac output. The flow is derived from the 
two sources, the portal vein and the hepatic artery. The portal vein provides about three 
fourth of the blood flow, after passing through, the gastrointestinal capillary bed. The 
hepatic artery delivers the remaining one fourth of the blood [6]. 
Figure 1.1 Schematic diagram of the Liver structure (From B. A. Saville, 
M. R. Gray, Y. K. Tam, "Models of Hepatic drug elimination", 
Drug Metabolism Reviews, 24(1), 49- 88, 1992) 
1.1.1 Physiology of Liver 
The basic functional unit of the liver is the liver lobule, which is a cylindrical structure. 
The human liver contains 50,000 to 100,000 individual lobules. The venous sinusoids are 
lined by two types of cells (1) Typical endothelial cells and (2) large kupffer cells, which 
are tissue microphages. The endothelial lining of the venous sinusoids has extremely 
large pores. Beneath this lining, lying between the endothelial cells and hepatic cells, is a 
very narrow tissue space called the space of Disse. Because of the large pores in the 
endothelium, substances in the plasma move freely into the space of Disse. Kupffer cells 
are capable of phagocytizing bacteria and other foreign matter in the blood [7]. 
Orally administered substances are absorbed in the gastrointestinal tract, and enter 
the liver through the portal vein. Drugs administered intravenously circulate through the 
body and enter the liver through both hepatic artery and portal vein [2]. The liver 
contains about 15% of total blood volume of the body. The liver constitutes an important 
blood reservoir in humans. 
The liver is a continuous meshwork of highly interconnected blood spaces. The 
sinusoidal channels are of varying length and are oriented in a nearly random fashion. 
Mixing can occur at various sites within the liver, especially at each node corresponding 
to the divergence and convergence of a number of sinusoids. Furthermore, back mixing 
within the organ occurs due to flow reversal in the sinusoids. Hepatic metabolism is 
highly dependent upon the physical properties of the substrate relative to the physical 
characteristics and intrinsic activity of the liver. Every hepatocyte is exposed to the 
blood, since the plates of hepatocytes are no more than two cells thick. The hepatocytes 
remove substances from the blood and secrete them in to bilary canaliculi lying between 
the adjacent hepatocytes. The countercurrent relationship between the bile flow and 
blood flow within the lobule minimizes the concentration to the liver's efficiency in 
extracting substances from the blood [8]. To investigate the vast range of phenomena that 
affect hepatic metabolism, several classes of compounds can be used as probes of 
intrahepatic mixing, interphase transport and elimination [2]. The intimate contact of a 
large fraction of the hepatocyte surface with blood contributes to the ability of the liver 
to clear the blood effectively of certain classes of compounds. The organ  must be 
considered as a heterogeneous system to account for the transport between the 
vasculature and the cells W. 
1.1.2 Functions of Liver 
The basic functions of the liver can be divided into (1) vascular functions for storage and 
filtration of blood (2) metabolic functions concerned with the majority of the metabolic 
systems of the body, and (3) secretory and excretory functions that are responsible for 
forming the bile that flows through the bile ducts into the gastrointestinal tract. The liver 
performs a wide variety of functions. Some of them are endocrine functions, clotting 
functions, digestive functions, organic and cholesterol metabolism, excretory and 
degradative functions [9]. The liver regulates the metabolism of carbohydrates, lipids and 
proteins. The liver transforms and excretes a large number of drugs and toxins. Drugs 
and toxins are frequently converted to inactive forms by reactions that occur in 
hepatocytes. Drug transformations that occur in hepatocytes are oxidative, acetlyation, 
methylation, reduction, and hydrolysis. The transformation that occurs in the liver 
renders many drugs more water soluble, and thus they are more readily excreted by the 
kidneys. Some drug metabolites are secreted into bile. The liver has a very active 
chemical medium and this medium is well known for capability of detoxifying or 
excreting into the bile many different drugs including sulfonamides, penicillin, 
ampicillin, erythromycin, and many others. In a similar manner several of the different 
hormones secreted by the endocrine glands are either chemically altered or excreted by 
the liver, including thyroxin. 
A heterogeneous model was used to study hepatic elimination of the liphophilic 
compound lidocaine and its metabolites. Simulations were done on a 486 based personal 
computer with the VisSim (Visual Solution Inc., Westford, MA) graphical modeling 
program. A sensitivity study was done which established ranges of kinetic constant 
values that can be used. The heterogeneous model had to be changed slightly to simulate 
the antiarrthymic drug procainamide. Simulations were done for procainamide and range 
of kinetic constant values were determined. 
CHAPTER 2 
METHODS 
The following chapter documents the methods available for modeling kinetics of liver 
metabolism. The method used is described in detail. Equations and parameter values are 
described. Simulations were done on VisSim software [10]. 
2.1 Types of Models Available 
There are three types of models available for liver metabolism; which include 
(1) Non-parametric models, 
(2) Homogenous mixing models, 
(3) Heterogeneous models 
Hepatic metabolism models may be classified according to the assumption made in the 
liver physiology and degree of mixing within the organ. Non-parametric models are the 
simplest kind of models. These models do not have any adjustable parameter to describe 
extent of mixing and interphase transport. A second class of models are homogenous and 
these models take into account the extent of intra hepatic mixing. However these models 
do not explicitly account for mass transfer between the cells and the vasculature. Both 
non-parametric models and homogenous models are described by first order ordinary 
differential equations. The heterogeneous models are divided into two types. The first 
type uses homogenous compartments to describe intrahepatic mixing and this type 
assumes complete mixing on a microscopic level. The second type assumes little or no 
mixing on a microscopic level [2]. Microscopic heterogeneous models (no mixing) use 
partial differential equations and are distributed parameter models. These models are 
more complex then the earlier types described. 
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2.1.1 Non-Parametric Models 
The most commonly used and most extensively investigated models of hepatic 
elimination are the well stirred model and parallel tube model. Both models ignore the 
heterogeneous nature of the liver, assuming that compounds are equally and 
instantaneously distributed between the vascular and cellular regions of the liver. Both 
models can be mathematically described by the same Taylor series expansion [11]. A 
well mixed model is mathematically simple. However, it cannot describe the metabolism 
of materials which are limited by the transport into the hepatocytes. A parameter model 
is more complex mathematically. Pang and Rowland [12] demonstrated that weak 
dependence of the lidocaine metabolism upon flow rate was best described by the well 
mixed model. These types of models are mathematically simple and cannot be used to 
describe intra hepatic mixing. Well mixed and parallel tube model, require so many 
approximations as to limit their use to a small selected number of substrates. Non 
parametric models can be described by ordinary differential equations. 
2.1.2 Homogenous Models 
These types of models are mixing models, and are used to describe mixing phenomena 
that occur in the liver. There are two single parameter homogenous models for hepatic 
mixing (1) The axial dispersion model [11, 13-16] 
(2) The series compartment model [17] 	 • 
Both these models are based upon well established models for chemical reactors [18]. 
The axial dispersion model assumes that the liver is a packed bed in which different 
degrees of axial mixing can occur. The dispersion model is mathematically complex and 
is used mainly as an empirical model. The series compartment model is mathematically 
simple and is very general for species without transport limitations. Axial dispersion 
models are described by partial differential equations. The series compartment model 
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does not include the effect of transport processes between the vascular and cellular 
regions of the liver. The disadvantage with both types of homogenous models is that 
there is no direct means of accounting for physiological phenomena such as interphase 
mass transport and variable flow through the liver. 
2.1.3 Heterogeneous Model 
The heterogeneous model is required to properly investigate transport process in the liver 
[2]. Heterogeneous models are typically more complex than homogenous models. 
Several models for heterogeneous metabolism have been developed with varying degree 
of complexity. Heterogeneous models explicitly account for transport processes between 
species in the cells and the vasculature. The heterogeneous models proposed by Tsuji 
[19] were used for a variety of antibiotics but this model has drug specific assumptions 
and cannot be used as a general model. The Deans-Levich model [20] and the finite stage 
transport model [21] are promising but require modifications to be made before they can 
be used for liver metabolism. The compartment model proposed by Weisiger [22] has 
several advantages such as mathematical simplicity, requires minimum data and is easy 
to use as a predictive model for both drugs and metabolites. This model can account for 
several physiological processes such as cellular uptake and release as well as intracellular 
reactions. The compartment model proposed by Weisiger [22] and modified by Saville 
[1] comes closest to the ideal model for liver metabolism. The modified model can be 
used to describe time dependent profiles of a variety of compounds. Experimental 
evidence suggests that this is particularly effective for species subject to passive 
transport. Hence, this model was used for the liver metabolism. The model is 
mathematically simple, and can account for a wide variety of physiological phenomena 
and is easy to use both for correlating data and as a predictive model [2]. 
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The heterogeneous model proposed by Weisiger [22] and modified by Saville [1] 
produced a best fit of the data and was used to model hepatic elimination of lidocaine and 
its metabolism. A similar model was used to model hepatic elimination of procainamide. 
There are two types of enzyme inactivation. (1) Chemical moves in to the cell and 
enzymes breakdown chemical in the cell. (2) Enzymes moves outsides cell and 
breakdown of chemical occurs outside cell. In lidocaine breakdown occurs inside cell. 
While in procainamide breakdown occurs outside cell. 
2.2 Model for Lidocaine Metabolism 
The liver model for the lipophillic compound lidocaine consists of two compartments: an 
extracellular compartment and a cellular compartment [1]. Experimental evidence 
indicates that the concentration of substances in the space of Disse is very close to the 
concentration of the substances within the sinusoids, since the fenestrate are large [22]. 
Lidocaine undergoes linear oxidative deethylation of the tertiary amine group and forms 
monoethlglycinexylidide represented as MEGX. Lidocaine also undergoes hydroxylation 
of the aromatic ring to form 3-hydroxylidocaine represented as 3-OHLID. These two are 
the important metabolites of lidocaine. 
2.2.1 Assumptions and Equations 
(1) The general model consist of a series of repeating cellular-extracellular parallel 
compartments. 
(2) The sinusoids and the interstitial space of Disse are approximated as a single unit 
called the extracellular compartment. 
(3) The second compartment is the tissue or cellular compartment. This compartment is 
assumed to behave as a homogenous pool for both reaction and efflux. 
(4) Mass transfer takes place between these two compartment by kinetic rate constants 
k12 and k21. 
(5) Metabolites are formed in the cellular compartment. 
(6) The number of composite compartment units does not influence the effectiveness of 
this model in representing washout profiles of lidocaine and its metabolites. The reason 
for this is that time to complete cellular uptake and release is significantly longer than the 
time require to clear the extracellular network [I]. Therefore for our purpose we choose 
N=1. 
(7) Inputs and outputs are by way of the extracellular compartment only. 
Figure 2.1 Compartment model for hepatic elimination of lidocaine and its 
metabolites (From B.A. Saville, M.R. Gray, and Y. K. Tam, 
"Experimental studies of transient mass transfer and reaction in 
the liver, Interpretation using a heteregenous compartmental 
model", J Pharm. Sci., 81(3), 265-271, 1992) 
The model shown in Figure 2.1 to describe liver metabolism was first proposed by 
Weisiger [22] and then modified by Saville [1]. There are 'N' number of extracellular and 
cellular compartments arranged in series parallel order. Compartments '1' and '2' 
represent the cellular and extracellular compartments respectively. The concentration of 
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cellular and extracellular compartments is represented as C1j 
 and C2j respectively. 'Q' is 
the blood flow in to and out of the cellular compartment. Cin is the input to the cellular 
compartment. As seen in Figure 2.1 'j' is the number of compartments. For lidocaine 
'j'=1. Mass transfer equations for Figure 2.1 are given as 
V1j [ C1j / dt]= Q (Cin - C1j) - k12V1jC1j + k2Vl2jC2j 	 (1) 
V2j[dC2j/dt ] =kl2V1jClj - k2lV2jC2j - V2jkrC2j + V2jkfCp2j 	 (2) 
Where: 
V1j  = Volume of extracellular compartment (mL) 
V2j = Volume of cellular compartment (mL) 
Q = Volumetric flow rate through organ (L/min) 
Cin = Input concentration (uM) 
Clj = Concentration in extracellular compartment (p.M) 
C2j = Concentration in cellular compartment (i.tM) 
Cp2j = Precursor concentration in the cellular compartment (µM) 
Cm2j = Metabolite concentration in the cellular compartment (p.M) 
k12 = Rate constant of uptake in to liver cells from extracellular space (min-1) 
k21 = Rate constant of release in to liver cells from extracellular space (min-1) 
kf = Rate constant for intracellular formation (min-1) 
kr = Rate constant for intracellular reaction (min-1) 
Figure 2.2 Metabolites formation of lidocaine. 
Figure 2.2 shows the reactions occurring in the cellular space when the species of interest 
C2j  reacts to form metabolites Cm2j. Metabolites are formed in the cellular compartment 
by the kinetic rate constant kr. Depending on the rate constant, metabolite formation 
occurs. If kr increases then metabolites form quickly and if kr decreases then metabolites 
form slowly. 
2.2.2 Calculations 
Vlj  and V2j are calculated as ; 
Vlj 	 = Vv / N; V2j = VC / N 	 (3) 
N is the number of compartmental units 
N = 1 for Lidocaine and its metabolites 
Vv is extracellular volume (rnL) 
VC is Cellular volume (mL) 
Vtot = VC + VV 	 (4) 
Where Vtot is the total physiologic volume of the liver (mL) 
f he volume of the cellular region is nearly six times that of the extracellular region [1]. 
V2j = 6 * (V1j) 	 (5) 
Vtot = Wl/fl 	 (6) 
Where WI = Liver weight (g) 
f l = Density of liver (g/L) 
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All experiments used rat livers isolated from male Sprague-Dawley rats [1]. Rats were 
anesthetized with diethyl ether, and the liver was isolated by surgical cannulation of the 
hepatic and portal veins and inferior vena cava. The bile duct was not cannulated. During 
experiment, the organ was kept moist and at a physiological temperature. Concentrated 
lidocaine was infused with a syringe pump. Samples of the inlet concentration were taken 
every 10 min to verify the infusion rate and to ensure that a constant concentration at the 
inlet was maintained. For washout experiments, lidocaine was infused until steady state 
was reached. Drug infusion was then stopped. Samples of the liver effluent were 
optioned every 6 seconds. Parameters for this model were estimated from the 
experimental data [1, 22] at a standard set of conditions. 
WI= 10 gms 11= 1 g/L 
Therefore, Vtot = 10 mL (from equation (6)) 
Using equations (3), (4), and (5) 
V1j 	 1.4285 mL and V2j = 8.571 mL 
From [22] at standard test condition 
Wl/Q = 0.33 but WI = 10 g Therefore Q = 30.30 L/min 
Next kinetic rate constants were estimated. The most important consideration in 
modeling the metabolism of lipophilic compounds in the liver is the proper estimation of 
the kinetic time constant values. When the model was simulated on a 486 based personal 
computer with VisSim (Visual solution Inc.,) [10] software with kinetic constant values 
published in reference [1], it was found that the system was unstable. Kinetic rate 
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constants values given in reference [1] for k12 and 101 were 1206 = 830 min -1 and 46 
39 min -1 respectively for lidocaine. When model was simulated with these kinetic rate 
constant washout profile were unstable. Concentration was getting very high value in 
range of thousands of micomolar. Also concentration was achieving negative values 
which is impossible. With kinetic constant values published in reference [1] for lidocaine 
metabolites MEGX and 3-OHLID concentration reached very high value and also 
negative values. 
2.2.3 Data Analysis 
We then used the exponential peeling method [24] to obtain parameters which 
characterized the experimental curves presented in reference [1]. We used these values in 
the heterogeneous model. 
Model equations (1) and (2) were solved analytically for N = 1. This solution was 
compared with the exponential peeling equations and kinetic constants were estimated 
which then allowed us to fit the experimental data. Table 2.1 gives the comparison of the 
kinetic constant values which are given in the reference and values which were obtained 
by the exponential peeling method. It is seen that there is vast difference in the values 
between the two. 
Table 2.1 Comparison of kinetic constants values for lidocaine given in the reference 
and predicted after exponential peeling method 
Values given in the reference Predicted value 
k12 = 1206 ± 83 min -I  k12 = 9.7 min -1  
Ic.7 	 ----- 46 	 ± 39 min -1 	 k21 = 0.48 min - 
kr ----- 0.49 ± 0.16 min - kr = 0.49 min 
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By comparing this results, it was seen that the values for k12 and k21 were 100 times less 
than those reported in reference [1]. Difference in the values of kinetic rate constant may 
be due to typographical error. This was then repeated to obtain kinetic constant values for 
the lidocaine metabolites. The rate constant values were changed accordingly and new 
predicted values were obtained are shown in table 2.2. 
Table 2.2 Predicted rate constant values for lidocaine metabolites 
Rate constant MEGX 3-OHLID 
.1(12 (min-I) 0.38 2.2 
121 (min-1) 0.03 0.08 
kr 	 min- I) 0.24 0.35 
Simulation was done using these parameters on a 486 based personal computer 
using VisSim software [10]. It was observed that the system behaved in a predictable 
way. These parameters values were then used in a sensitivity study and a range of values 
were determined for lidocaine and each of its metabolites. 
The results obtained were compared with the experimental results or data 
presented in reference [1]. It was found that the washout profile was very similar to the 
one given in the reference. Simulation curves are kept in the appendix A. It was found 
that the heterogeneous model accounts for the slow elution of the drug and its 
metabolites. 
Encainide is a highly effective, well tolerated antiarrthymic agent [25]. We tried 
to model metabolism of encainide in the liver but were unsuccessful due to reasons stated 
below; (1) There are few models available for modeling encainide metabolism. (2) The 
models that are available contain so many simplifying assumptions that they are not 
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useful for a heterogeneous organ such as liver [26,27]. Therefore, another antiarrthymic 
drug procainamide was modeled [28-30] 
2.3 Model for Procainamide 
The model which was previously described for lidocaine was used to model 
procainamide with appropriate changes. Figure 2.4 describes the model and it is 
represented by differential equations (7) and (8). 'u' is the amount of procainamide 
present in urine. This parameter is taken in to account as procainamide is excreted in 
urine with sufficient quantity so that it must be considered. It should be noted that 
metabolism and breakdown occurs in the extracellular compartment. Therefore rate 
constant for breakdown is included in the extracellular concentration equation. 
Breakdown of procainamide in the extracellular compartment is due to the enzymes 
which inactivates it. These are the changes which differ from the lidocaine model. 
V j [dC 1j / dt] = Q 	 2 V 	 21 V2j C2j-kr V1j Cij - u Cij(7) 
	
V2j [dC2j /dt] = k12 V 
	 -101 V7 	 (8) 
Values for the kinetic constants and other parameters used in equations (7) and (8) were 
obtained from [3,28]. However, the same values of Q, V 1 j, V2j were used as in the 
lidocaine model. The reason for this is that the extracellular and cellular volumes and 
flow are expected to be similar for both drugs. 
Figure 2.3 Metabolite Formation of Procainamide 
Figure 2.4 Comparmiental model for hepatic elimination of procainamide 
2.3.1 Calculations 
Cm lj is the metabolite of 
kr  is the rate constant for metabolite formation 
k12 = 9.35 min -1  
k21 = 9.35 -min -1  
kr = 0.0053 min -1  
u = 0.0013 ml/min/mole 
Cin  = 20, 50, 70 mg/kg (single impulse injection) 
u is the concentration of Procainamide in urine output 
Cin is converted from mg/kg to 
Molecular weight of Procainamide hydrochloride = 271.79 
mg/kg--> 10 µg/kg (mol. wt.) --> µM 
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Using this formula different values of Cin are obtained; 
5.4358 µM for 20 mg/kg 
13.5895 µM for 50 mg/kg 
19.0253 µM for 70 mg/kg 
Using these data and equations (7) and (8) simulations of the pharmacokinetics of 
the procainamide in the liver were done using VisSim software 110] on a 486 based 
personal computer. A parameter sensitivity study was also done to determine the range of 
values for the kinetic rate constants for which the model is stable. Results are placed in 
chapter 3. 
CHAPTER 3 
RESULTS AND DISCUSSION 
The following chapter discusses the results of the simulations. The range of kinetic 
constants which can be used in the stable operating range and sensitivity study are 
described in detail. The simulation results and block diagram of differential equations are 
kept in appendix A. 
3.1 Lidocaine and its Metabolites 
3.1.1 Washout Simulations 
The clearance of lidocaine and its metabolites MEGX and 3-OHLID from the liver were 
simulated by loading the system with an initial concentration of each drug. For each case 
an initial condition was set in the integration block [step( hepatic loading )] and no input 
was given to the model to simulate washout experiments. It was observed that the 
concentration decreased exponentially with time. These results matched the data [1] from 
washout experiments after cessation of drug administration. Curve 1 shows these results. 
The simulation profiles indicate that the concentration of lidocaine and its metabolites 
declined in a first order fashion (Curve 2, 3, and 4). These results are consistent with the 
results obtained by radiolabeled lidocaine and supports the conclusion that drug 
transport and release in the liver are linear. 
It is observed that lidocaine concentration is higher than its metabolites in both the 
cellular and extracellular compartments because lidocaine is the major chemical (drug) 
while MEGX and 3-OHLID are its metabolites. All three drugs take nearly the same 
amount of time to "washout" of the liver. The model also predicts that MEGX and 3-
OHLID are eliminated faster than lidocaine. 
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33,2 Sensitivity Study 
A parameter sensitivity study establishes the range of kinetic constants for which the 
model is stable. It was determined that, if the sensitivity range is exceeded, the cellular 
and/or extracellular concentrations become negative or approach zero. The sensitivity 
study was done by using a steady state (step input) input along with an initial condition 
(hepatic loading). This is similar to the experimental setup in which the perfused liver is 
first infused with drug to reach a steady state condition and then the drug is administered 
at a constant rate after some predetermined time period. The maximum values of the 
kinetic constants were determined at the stage where the system response was different 
from the normal behavior. A step input was given, the kinetic constant value of one 
parameter was either increased or decreased and kinetic constant values of other 
parameters were unchanged. Simulations were done and these steps were repeated until 
abnormal behavior in the model was observed. When the cellular and extracellular 
concentration decreased or diminished, instead of increasing, this define the maximum 
value and sets the upper limit for the kinetic constants for the model. Similarly, the lower 
limit is set when simulated extracellular and cellular concentrations approached zero or 
became negligible. It was seen that the rate constant for uptake was significantly different 
for each drug and was lowest for MEGX and highest for lidocaine. This shows that 
lidocanie is the drug which is taken in from compartment 1 to 2 very fast compared with 
its metabolites. Similarly, the rate constant for release of the drug from the cells differed 
for each drug. It was lowest for MEGX and highest for lidocaine. This shows that MEGX 
takes the longest time to come out of compartment 2 to 1 and lidocaine takes the shortest 
time. Curve 5.A shows the washout profile of lidocaine and its metabolites taken from 
reference [1]. Curve 5.B shows the simulation results of washout profiles for lidocaine 
and its metabolites (no input). It is seen that Curve 5.A and Curve 5.B looks similar. 
Curve 5.0 shows simulation results with a step input and with initial conditions. The 
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extracellular concentrations increased and attained a new steady state value in a short 
period of time. Thereafter, the extracellular concentration remained constant. The 
cellular concentration remained unchanged for a step input because input does not affect 
cellular concentration directly. 
3.1.2(a) Sensitivity Study of Lidocaine 
Curves 6.A and Curve 6.13 (cellular concentration of lidocaine with less effective change) 
show a simulation in which the liver is loaded with an initial concentration of lidocaine 
and then a step input is applied at some predetermined time. It is observed that for 
nominal values of the parameters the extracellular concentration first decreases 
exponentially and then increases exponentially to attain a steady state value after a long 
time. When the kinetic constants are set at their maximum values, it is seen that 
extracellular concentration starts decreasing. Using minimum values of the kinetic 
constants the extracellular concentration reaches a value nearly equal to the step input in 
a very short period of time. When the kinetic constants are increased to their maximum 
values, the cellular concentration decreases to a very low value (Curve 6.B). When the 
minimum values of the kinetic constants were used there was no effect of the step input 
on the cellular concentration. It remained constant for all time. Thus, no significant 
changes were observed for cellular concentration with input. Hence, cellular 
concentration curves are not included for lidocaine metabolites. 
3.1.2(b) Sensitivity Study for MEGX and 3-OHLID 
Curves 7, and 8 show the simulation for lidocaine metabolites MEGX and 3-OHLID 
respectively. When the maximum value of the kinetic constants were used the 
extracellular concentration of both metabolites starts decreasing, while cellular 
concentration approached zero. At the lower limit for the kinetic constants the 
extracellular concentration of both metabolites reached very high values equal to the 
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steady state input, whereas the cellular concentration of both metabolites remained 
unchanged for the entire simulation time period. The reason for the unchanged cellular 
concentration is that the kinetic constants are so low that they do not affect the cellular 
concentration. In other words nothing comes in and nothing goes out of the cellular 
compartment. The maximum values of the kinetic constant represent very fast rates of 
uptake and release. This leads to concentrations in the extracellular compartment below 
their initial value and negative values for the extracellular concentration. The ranges of 
the kinetic constants are summarized in table 3.1. Table 3.1 shows the summary of values 
of kr, k21, kr. 
Table 3.1. The range of values for k12, k21, and kr for lidocaine and its metabolites 
k17 min-1  k21 min-1  kr min- 
Chemical Min Max Min Max Min Max 
 Lidocaine 0.0 18.1 0.0 8.75 0.0 11.75 
 MEGX 0.0 18.4 0.0 16.45 0.0 12.35 
3-OHLID 0.0 18.58 0.0 13.0 0.0 2.75 
Maximum values of k12 and k71  which can be used simultaneously are given in Table 
3.2. kr value denotes the rate constant of breakdown which can be used along with these 
maximum values to give a stable model response. 
Table 3.2 Maximum values of both k12 and k71 which can be used together 
Chemical k17 min 	 t k21 min -1 	
 kr min 
Lidocaine 10.7 3.25 0.49 
3-OHLID 	 10.7 
 
7.76 0.35 
MEGX 12.58 6.35 0.24 
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The volume of the cellular compartment is nearly six times that of the extracellular 
compartment. Thus, at steady state there is close to thirty times more material in the 
cellular space than in the extracellular space. This shows that cells can acts as a large 
reservoir for the drug and its meatabolities. Hence, it takes time to fill the extracelllular 
compartment (drug uptake). It takes time to empty the cellular compartment (drug 
washout). Normal values are ones for which results of simulation are consistent with the 
results published. Table 3.3 summarizes the normal values of kinetic rate constants. 
Table 3.3 Normal value of kinetic constant for lidocaine and its metabolites 
Chemical k12 min-1  k21 min-1 kr min-1  
Lidocaine 9.7 0.48 0.49 
MEGX 2.2 0.08 0.35 
3-OHLID 0.38 0.03 0.24 
It is seen that changing flow (Q) has no effect on extracellular or cellular 
concentrations. The reason for this is that the transport process is barrier limited. There 
are two types of transport processes (1) flow limited and (2) barrier limited. 
Flow limited: 
Transport out of the compartment into the extracellular space is very rapid. 
Therefore if flow is increased more material is brought to the transport site and increases 
the amount of material transported. 
Barrier limited : 
Transport out of the compartment into the extracellular space is very slow so it 
does not change very much if more material is brought to the transport site by increasing 
flow. 
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3.2 Procainamide Simulations 
For the antiarrthymic drug procainamide the heterogeneous model used is similar to that 
used for lidocaine. For procainamide, metabolism occurs in the cells and hence the 
differential equations for the cellular and extracellular compartments are modified 
accordingly. Procainamide elimination occurs in urine [30] and that factor is included in 
the model. Urine output is added to the extracellular compartment. Procainamide 
metabolites are not important so they were not considered. With these changes 
differential equations (8) and (9) were simulated on a 486 based personal computer using 
VisSim (Visual Solution Inc.) software. Procainamide simulations are divided into 
washout profiles, simulations with input and sensitivity study of different kinetic rate 
constant parameters. Each of them is described in detail. 
3.2.1 Washout Profile 
Washout of procainamide is simulated using an initial condition in the integration block 
(similar to the lidocaine washout simulation). Curve 9 shows the simulation. As time 
increases the extracellular and cellular concentrations of procainamide decrease 
exponentially in a first order fashion. It is seen that drug elimination is faster in the 
extracellular compartment than the cellular compartment, because more concentration 
leaves the compartment than enters the compartment. The rate of cellular uptake and the 
rate of cellular release are assumed to be same for procainamide because it is not lipid 
soluble. Hence, the same amount of time is taken by cellular compartment to take up 
procainamide and to release procainamide. 
3.2.2 Simulation with Input 
Curve 10 shows the simulation of a bolus injection of procainamide. This input is similar 
to a pulse of very short duration. Both cellular and extracellular concentrations are shown 
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along with the input. In this simulation no procainamide is present initially in either of 
the compartments. It is seen that the extracellular compartment acts as a reservoir and its 
concentration increases rapidly with the impulse (bolus injection). The maximum value 
attained by the extracellular compartment is nearly equal to the peak of the impulse and 
thereafter, extracellular concentration decreases suddenly to a zero value. The rise in 
concentration is exponential but the fall in concentration is not exponential. The reason 
for this is that before the concentration reaches saturation level in the extracellular region 
the impulse starts to decrease causing the extracellular concentration to decrease. The 
cellular concentration acts exactly as any linear system should act. The cellular 
concentration increases exponentially and reaches its steady state value during the time 
period of the impulse. When the impulse starts decreasing the cellular concentration also 
starts to decrease in an exponential way. The amount of procainamide in the cellular 
compartment is smaller than that in the extracellular compartment, because the cellular 
compartment volume is greater than the extracellular compartment volume. It is also seen 
that the time taken to reach saturation level during the impulse is higher in the 
extracellular compartment than in the cellular compartment. 
3.2.3 Sensitivity Study for k12 
Curves 11.A and 11.B show the results of the sensitivity study done on the liver model 
for procainmide for k12. It shows the range rate of uptake from the extracellular 
compartment to the cellular compartment for extracellular concentration and cellular 
concentration respectively. Within the given range the Curve 11.A shows the simulations 
of extracellular compartment for which model is stable. The minimum and maximum 
curves represent the lower and upper limit of k12. It is seen that when k12 is reduced 
significantly with respect to k21, the extracellular concentration reaches a value above 
the impulse amplitude value. This is not a realistic occurrence, hence this sets the lower 
limit for k12. During the decreasing portion of the impulse it is seen that the extracellular 
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concentration decreases, then increases and then decays exponentially. This is similar to 
an overshoot in an electrical system. On the other hand when k12 is increased and made 
much larger than k21, it is seen that the extracellular concentration reaches negative 
values when the impulse starts decreasing. This is not physically possible so this sets the 
upper limit for k12. Curve 10.B shows the curve for cellular concentration with different 
values of k12 with respect to k21. It is observed that for lower value of k12 cellular 
concentrate becomes very low, while for higher values of k12, cellular concentration 
reaches very high values. 
3.2.4 Sensitivity Study for k21 
Curves 12.A and 12.B show the effects of changes in the rate constants k21 with an 
impulse as input, with no initial condition on cellular and extracellular concentrations 
respectively. Curve 12.A shows the simulation results when the kinetic constant k21  is 
changed for the extracellular compartment (k21 is decreased compare to k12). This is 
physically represented as a longer time for the drug to be eliminated from the cellular 
compartment. Simulating this condition, it was found that during the increasing part of 
the impulse the cellular concentration increased in a linear manner and during the 
decreasing phase of the impulse the cellular concentration decreased exponentially. It 
was seen that a longer time was taken before the whole drug was completely eliminated 
from the cellular compartment (Curve 12.B). This is consistent with the physical 
interpretation. With k21 increased it is seen that during the increasing phase of the 
impulse period, the cellular concentration reaches its steady state value quickly and then 
the cellular concentration remains constant. During the decreasing phase of the impulse 
the cellular concentration decreases rapidly. When the nominal value of k71 was used, 
cellular concentration increases exponentially, attains a steady state value at the end of 
the impulse period and then decreases exponentially with the decreasing period of the 
impulse. This is similar to any stable linear system response. 
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Curve 12.A shows the effect of k21 for different ranges of extracellular 
concentration. At the maximum value of rate constant k21, the extracellular 
concentration increases to a higher value than the input, while for the minimum value of 
k21 the extracellular concentration attains negative values. For the nominal value of k21, 
the extracellular concentration increases during the increasing phase of the impulse and 
then decreases during the decreasing phase of the impulse. 
3.2.5 Sensitivity Study for 'u' 
Curve 13 shows the results of the simulations for the range of the kinetic constant 'u' 
(urine). For increasing values of 'u' the extracellular concentration increases 
exponentially and before it reaches its steady state value, the impulse starts decreasing. 
The extracellular concentration then drops and returns to zero. At this value of 'u' the 
extracellular concentration attains higher value than the input. We consider this to define 
the maximum value of 'u' for this model. The curve for the nominal value of 'u' shows the 
action of a stable linear system. There is no lower limit of 'u' for extracelluar 
concentration. Cellular concentration changes less than 5% with changes in the value of 
'u', since 'u' does not effect cellular concentration directly. 
3.2.6 Sensitivity Study for kr 
The results of the sensitivity study of the rate constant of breakdown of the drug (kr) are 
shown in Curve 14. It is seen that when kr is made very high the extracellular 
concentration attains negative values for the decreasing phase of the impulse. This is 
overshoot and it is the characteristic of an underdamped system. Concentration can never 
attain negative values, thus this sets the upper limit for Kr. Physically increasing kr 
means that the breakdown of the drug is taking place faster than it is being formed. There 
is no lower limit for kr because, if kr is made very small a longer time is taken for its 
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metabolites to form and hence this will delay the formation of other metabolites. Cellular 
concentration is less affected by changes in the rate constant of breakdown kr. 
Thus, we have range of kinetic constants for procainamide which can be used for 
stable simulation of the model. Also there are normal limits during which the model 
behavior was similar to the predicted one. Table 3.4 summarizes the range of values for 
parameters for procainamide. 
Table 3.4 Procainamide simulations results with different ranges. 
Minimum Normal Maximum 
ki2 min-1  2.95 9.35 14.25 
k21 min-1 0.5 	 9 35 20.5 
u ml/min/mole 	 0 0.0013 6.78 
 kr min-1 	 11 0 
 	 I 	  0.0053 4.65 
CHAPTER 4 
CONCLUSIONS AND SUGGESTIONS 
4.1 For Lidocaine and its Metabolites 
The heterogeneous model represented by equations (1) and (2) is appropriate to 
describe the metabolites of the lipophilic compound lidocaine and its metabolites. 
Simulations were done for lidocaine and its metabolites and results obtained were 
consistent with published data [1]. Washout profiles of lidocaine and its metabolites 
exhibited a first order decline. With a step input the model behaved in a linear manner, 
for lidocaine and its metabolites. The kinetic constant for cellular uptake of lidocaine was 
higher than the kinetic constant for extracellular uptake. This states that lidocaine and its 
metabolites are distributed faster in the cellular region than in the blood compartment 
(since lidocaine is lipid soluble). The rate of conversion of lidocaine within the cells is 
much slower than the rate of release from the cells. Thus, the amount of lidocanie 
converted to metabolites will be significantly less than the amount of lidocaine 
transported from the cellular compartment. 
4.2 For Procainamide 
For the antiarrthymic drug procainamide, it was found that the rate constant of uptake 
from the extracellular compartment to the cellular compartment and the rate of release 
were identical (procainamide is not lipid soluble). Sensitivity study estimated the upper 
and lower limits for each rate constants. The simulations done provided insight of kinetic 
constants and metabolism of procainamide in liver. 
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4.3 Future Work 
The heterogeneous model presented in this thesis can be readily modified to include 
enzyme inactivation. Also the model can be used to study the interactions of two or more 
drugs if the interaction constants can be obtained. It will be interesting for the model to 
be tested for simulating concentrations of toxic chemicals such as halogenated 
hydrocarbons as well as other critical drugs. The heterogeneous model developed for 
local anesthetic drug lidocaine can be used along with other models developed for 
cadiovascular, respiratory and cerebral systems to simulate the overall effect of lidocaine 
on the body. In this manner other drugs and toxic chemicals such as halogenated 
hydrocarbon metabolism can be modeled and their effects can be simulated. The 
heterogeneous model is capable of describing the time dependent profile of a variety of 
compounds. 
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Figure A4 Block Diagram of Cellular Compartment of Procainamide 
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Curve 1 Washout Profile of MEGX from reference [1] 
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Curve 2 Simulation of Washout Profile of Lidocaine 
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Curve 3 Simulation of Washout Profile of MEGX . 
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Curve 4 Simulation of Washout Profile of 3-OHLID 
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APPENDIX B 
VISSIM DESCRIPTION 
VisSim (Visual Solution Inc., Westford, M.A.) is a powerful set of software with the 
ability to design, simulate, plot, and debug within a single interactive environment. 
Models and systems are built using blocks. Blocks are connected to each other and to 
displays using flex wires. Blocks and flex wires are the primary tools of VisSim. 
There are two types of blocks (1) standard blocks and (2) compound blocks. 
Standard blocks includes (l) Addition block, (2) Arithmetic block, (3) Integration, (4) 
Non-linear, (5) Boolean etc. A compound block is the combination of more than one 
standard block. There are also signal producing and signal consuming blocks. The signal 
consuming block include plot which is the output of any system in the form of a graph 
with time, frequency or parameter varying on 'y' axis. Signal producer block includes 
step, sinusoids, unknown etc. Any of these blocks can be used to represent a physical 
situation or to produce a signal. An example of this is that a bolus injection of a drug can 
be mathematically represented as an impulse. Consider the case, where a bolus injection 
is given between time 3 to 5 sec. For any other time the signal produced is zero. This is 
represented mathematically as shown below; 
y = I for 3 < t < 5 
else 	 y = 0 
This condition can be simulated using two step blocks and a summer block. By setting 
the proper time for the step block and adding one block (with t=3) and subtracting one 
(with t=5) a pulse of fixed duration of 2 second is produced. A step input can be used 
whenever the input is constant to the system after some predetermined time period. There 
are output connector tabs with triangular shapes which helps the user to view the 
direction of the signal. Each block has two 
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(Block Diagram of A(d2x / dt2) - B(dx/dt) + Cx = 0) 
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types of signals (I) input signal or coming in signal and (2) output signal or exiting out 
signal. 
In modeling the hepatic system for drug elimination, there are two differential 
equations; one for the cellular compartment and one for the extracellular compartment. 
These equations were represented by blocks on the VisSim (Visual Simulation Inc., 
Westford, M.A.) software. VisSim has the ability to solve several types of differential 
equations, including ordinary differential equations (OBE's). VisSim solves ODE's by 
using an integration operator. The example below shows how VisSim solves a second 
order differential equation. Let the equation be; 
A(d2x /dt 2 ) - B(dx/dt) + Cx = 0 
Since integration is more numerically stable than differentiation, the above equation can 
be represented in terms of integrators. If we use 1/S (Laplace Operator) as a short hand 
notation for an integrator, then x(t) can be represented by; 
x(t) = I /S [dx/dt] = (1/S) [1/S (d 2x) /(dt2)] 
The original equation can be written in modified form as; 
2x / d 
	
/ A [ B (dx/dt) - Cx 
Figure on the opposite page shows block diagram of this differential equation. This 
equation is implemented on VisSim by wiring the output of the x and dx/dt variable 
blocks through two gain blocks (which represent 'C' and 'B' respectively). These two are 
then given as input to the summing block with a negative sign on the signal coming from 
the 'x' variable and a positive sign on the signal coming from the 'dx' variable. The output 
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of the summing block is divided by the constant block whose value is equal to 'A'. The 
output of this block is d2x/dt2. This diagram represents a closed loop system. From this 
loop values for x(t), dx/dt, d2x/dt2 can be tapped off and displayed using the signal 
consumer plot. Different values can be entered in appropriate blocks to simulate different 
sets of initial condition and system parameters. 
The procedure to built a file and simulate a differential equation is as follows; 
(1) From file menu create a new file 
(2) From blocks in the menu create appropriate blocks, then connect them properly using 
flex wires so that they represent the differential equation. 
( ) Insert proper values for parameters and initial conditions in the appropriate blocks. 
(4) Check that the system is closed loop and all signs are properly matched. 
(5) Create plot from the block menu and connect the outputs of the differential equations 
to the plot. 
(6) Go to edit menu and simulate the differential equation. 
REFERENCES 
[1] B.A. Saville, M.R. Gray, and Y. K. Tam, "Experimental studies of transient mass 
transfer and reaction in the liver, Interpretation using a heterogeneous 
compartmental model", J. Pharm. Sci., 81(3), 265-271, 1992. 
[2] B. A. Saville, M. R. Gray, Y. K. Tam, "Models of Hepatic drug 
elimination", Drug metabolism Reviews, 24(1), 49-88, 1992. 
[3] D. J. Cole, J. B. Naugwekar, "Effects of chronic ethanol ingestion on 
pharmacokinetics of Procainamide in rats", J. Pharm. Sci., 80(30), 
231-238, 1991. 
[4] R. L. Vick, Contemporary Medical Physiology, New York, Addison -Wesley 
Publishing Co., 1984, Ch. 51, pp 702-710. 
[5] R. S. Snell, Clinical Anatomy for Medical Students, Boston, Little Brown, 
1973, pp 175-262. 
[6] R. M. Berne, M. N. Levy, Physiology, 2 nd edition, St. Louis, The C. V. 
Mosby Co., Special Circulation, 1988, Ch. 35, pp 540-558. 
[7] A. C. Guyton, Textbook of Medical Physiology, 7 th edition, Philadelphia, W.B. 
Saunders Company, 1986, pp 835-838. 
[8] L. R. Johnson, Essential Medical Physiology, New York, Raven Press, 1992, 
Ch. 5, pp 501. 
[9] A. J. Vander, J. H. Sherman, D. S. Luciano, Human Physiology, 6 th edition, 
New York, McGraw Hill Publishing Company, 1994, Ch. 17, pp 561-600. 
[10] VisSim User's Guide version 1.2, Visual Solutions Inc., Westford, MA, 1993. 
[11] M. S. R. Roberts and M. Rowland, "Hepatic elimination: The dispersion model", 
J. Pharm. Sci., 74(5), 585-587, 1985. 
[12] K. S. Pang and M. Rowland, "Hepatic clearance of drugs II experimental 
evidence for acceptance of the 'well stirred' model over the 'parallel tube' 
model using Lidocaine in the perfused rate liver insitu preparation", 
J. Pharmacokin. Biopharm., 5(6), 655-680, 1977. 
[13] M. S. R. Robert and M. Rowland, "A dispersion model of hepatic elimination:1. 
Formulation of the model and bolus considerations", J. Pharmacokin. Biopharm., 
14(3), 227-260, 1986. 
[14] M. S. R. Robert and M. Rowland, "A dispersion model of hepatic elimination: 2. 
steady state considerations and influence of hepatic blood flow, binding within 
blood, and hepatocellular enzyme activity", J. Pharmacokin. Biopharm., 
14(3), 261-288, 1986. 
59 
60 
[15] M. S. R. Robert and M. Rowland, "A dispersion model of hepatic elimination: 
Application to metabolite formation and elimination kinetics", J. Pharmacokin. 
Biopharm., 14(3), 289-308, 1986. 
[16] M. S. Roberts and M. Rowland, "Correlation between in vitro microsomal 
enzyme activity and whole organ hepatic elimination kinetics: Analysis 
with a dispersion model", J. Pharm. Pharmacol., 38, 177-181, 1986. 
[17] M. R. Gray, Y. K. Tam, "The series compartment model for hepatic elimination" 
Drug. Metab. Dispos., 15, 22-27, 1987. 
[18] 0. Levenspiel, Chemical Reactions Engineering, New York, John Wiley 
Eastern & Sons, 1972, Ch. 61. 
[19] A. Tsuji, T. Yoshikawa, K. Nishide, H. Minami, M. Kimura, E. Nakashmia, 
T.Terasaki, E. Miyamoto, C. Nightingale and T. Yaman; "Physiologically based 
pharmokinetic model for Beta-lactam antibodies, I. tissue distribution and 
elimination in rats", J. Pharm. Sci., 72(11), 1239-1252, 1983. 
[20] B. A. Buffham and L. G. Gibilaro, "The analytical solutions of the Deans-Levich 
model for dispersion in pores media", Chem. Eng. Sci., 23, 1399-1401, 1968. 
[21] R. S. C. Rogers and R. P. Gardner, "Use of a finite stage transport concept for 
analyzing residence time distribution functions of continuos process", Am. Inst. 
Chem. Eng. J., 25(2), 229-240, 1979. 
[22] R. A. Weisigner, "Dissociation from albumin, A potentially rate limiting step in 
the clearance of substrates by the liver", Proc. Natl. Acad. Sci. ,USA, 82, 
1563-1567,1985. 
[23] B. A. Saville, M. R. Gray, Y. K. Tam, "III Evaluation of liver models for time 
dependent behavior", Drug Metab. Dispos., 15(1), 22-26, 1987. 
[24] M. L. Jones, G.M. Smith, J. C. Wolford, Applied Numerical Methods for Digital 
Computations, 3 rd edition, New York, Harper and Row, Ch. 4, pp 299. 
[25] M. Roden, S. B. Reele, S.B. Higgins, R. F. Mayol, R. E. Gammans, J. A. 
Oates, R. L. Woosely, "Total suppression of ventricular arrhythmia's by 
encainide", New Engl. J. Med., 302, 877-882, 1980. 
[26] J. T. Barbey, K. A. Thompson, 0. S. Echt, R. L. Woosley, D. M. Roden, 
"Antiarrthymic activity electrocardiographic effects and pharmacokinetics 
of encainide metabolites 0-desmethyl encainide and 3-methoxy-0-desmethyl 
encainide in man", Circulation, 77 (2), 380-391, 1988. 
[27] C. B. Mc Allister, H. T. Wolfenden, W.S. Aslanian, R. L. Woosley, G. R. 
Wilkinson, "Oxidative metabolism of encainide, polymorphism pharmacokinetics 
and clinical observations", Xenobiotica, 5, 483, 1986. 
[28] M. Roden, S. B. Reele, S.B. Higgins, G. R. Wilkinson, R. F. Smith, J. A. 
Oates, R. L. Woosely, "Antiarrhythmic efficacy, Pharmacokinetics and safety of 
N-Acetyl Procainamide in human subjects comparison with Procainamide", 
The Am. J. of Cardio., 46, 463-468, 1980. 
[29] K. S. Pang, J. C. Huang, C. Finkle, W. F. Cherry, S. Fayz, "Kinetics of 
Procainamide N-Acetylation in the rat in vivo and in the perfused rat liver 
preparation", Drug. Metab. Dispos., 12, 314-322, 1982. 
[30] 3. P. Uetrecht, R. L. Woosley, R. W. Freeman, B. J. Sweetman, J. A. Oates, 
"Metabolism of Procainamide in the perfused rat liver", Drug Metab Dispos., 
9, 183-187, 1981. 
61 
